Novel biologic Ab-IPL-IL-17 shows promise for rheumatoid arthritis and inflammatory bowel disease

Researchers have shown that a novel antibody generated to target an ‘essential amino acid sequence’ of both interleukin-17A and F has greater activity and potentially fewer side effects than existing biological therapies for conditions such as as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD).